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Abstract: Micellar electrokinetic chromatography (MEKC) was investigated for the simultaneous determination of letrozole, 
imipramine and their metabolites in human urine samples over a concentration range of therapeutic interest. Experimental 
parameters such as pH of the running electrolyte, sodium dodecylsulphate (SDS) concentration, borate concentration, voltage, 
etc were investigated. Under optimal conditions of 25 mM SDS, 15 mM borate buffer (pH 9.2), 15% 2-propanol, as back-
ground electrolyte; 28 kV and 40 ºC, as voltage and cartridge temperature, respectively; resolution between the peaks was 
greater than 1.7. Before the determination, a solid phase extraction (SPE) procedure with a C18 cartridge was optimized. 
Good linearity, accuracy, precision, robustness and ruggedness were achieved and detection limits of 12.5 ng/mL for letrozole 
and its metabolite and 37.5 ng/mL, were obtained for imipramine and their metabolites. Real determinations of these analytes 
in two patient urines were carried out. Sensitivity achieved in this method is sufﬁ  cient to perform kinetic studies in 
humans.
Keywords: micellar electrokinetic chromatography, letrozole, imipramine, breast cancer, antidepressant, ruggedness and 
human urine
Introduction
Many breast cancers rely on supplies of the hormone estrogen to grow. In women who have had their 
menopause, the main source of estrogen is through changing androgens (sex hormones produced by 
the adrenal glands) into estrogen; this occurs by an enzyme called aromatase. The conversion process 
is known as aromatization, and happens mainly in the fatty tissues of the body. Letrozole (LE) (trade 
name Femara
®) is a drug that blocks the process of aromatization, and so reduces the amount of estrogen 
in the body; drugs that work in this way are known as aromatase inhibitors. The recommended therapeutic 
dose for LE is 2.5 mg per day. The major metabolic elimination route of LE is by to bis-
4-cyanophenylmethanol (ME, its main metabolite) (Fig. 1). LE and its metabolite (ME) are excreted 
unchanged and their apparent elimination half-life time in plasma has been reported to be within 
approximately 2 days [1].
Often, mental disorders such as depression and anxiety may arise secondary to the presence of breast 
cancer and, it is therefore necessary to provide breast cancer patients with antidepressant treatment. 
Imipramine (IMI) is a tricyclic antidepressant (TCA) drug which is well absorbed in humans and under-
goes extensive metabolism in the body. IMI is metabolized into a major active metabolite, desipramine 
(DES), which exhibits an activity proﬁ  le similar to that of IMI and into two minor metabolites, 2-OH-
imipramine (2-OH-IMI) and 10-OH-imipramine (10-OH-IMI). To establish pharmacokinetic param-
eters, it is therefore important to monitor urine concentration of IMI and all their metabolites.
About the analysis of LE and ME in biological ﬂ  uids, to date, only a few methods have been reported. 
Marﬁ  l et al. published a high-performance liquid chromatographic (HPLC) method with a fully automated 
liquid-solid extraction and ﬂ  uorescence detection that offers high sensitivity for the quantiﬁ  cation of LE 
in plasma and urine, but not ME in either [2]. Mareck et al. reported a gas chromatography/mass spec-
trometric (GC-MS) method for determining these compounds; this method required a complex and long 
treatment of the urine with different steps, e.g. extraction, incubation of the sample for one hour, dryness 92
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evaporation, adding of organic solvent and ﬁ  nally 
a derivatization step [3]. Very recently, the authors 
of this work have also described a method to deter-
mine LE and ME in human urine by MEKC [4].
IMI and its demethylated metabolite (DES) have 
been determined in biological ﬂ  uids using tech-
niques such as HPLC coupled with ultraviolet and 
electrochemical detection [5–7], GC with nitrogen—
phosphorus [8], mass spectrometric (MS) detection 
[9, 10] and capillary zone electrophoresis (CZE) 
[11]. Nonaqueous capillary electrophoresis 
(NACE) was used to separate tricyclic antidepressant 
drugs in biological samples after online solid phase 
extraction in pharmaceutical formulations [12] and 
plasma samples [13]. The simultaneous determina-
tion of IMI and all its metabolites was carried out 
by Chen et al. using HPLC [14].
Nevertheless, less effort has been put in the 
development of analytical methods that allow deter-
mination of LE along with antidepressants in bio-
logical ﬂ  uids. These methods could be important 
because the joint administration of LE and antide-
pressants in patients with breast cancer, occurs 
frequently. Apparently, only one method has been 
published that uses MEKC for determining LE 
together with selective reuptake inhibitor (SSRIs) 
antidepressants and their metabolites in urine [15].
Capillary Electrophoresis (CE) can be regarded 
as an attractive separative technique due to its 
resolution, efﬁ  ciency, ready optimization, widely 
variable operating conditions, short analysis time, 
use of small volumes of analytes and little waste 
solution.
The goals of this report were to develop a 
simple, fast and sensitive CE method that enables 
simultaneous determination of LE and one TCA 
(IMI) together with all its metabolites in human 
urine. This analytical method can be not only of 
interest in clinical toxicology, but also in forensics 
as often the metabolites of several drugs are 
involved in intoxications. Besides, this method can 
be employed to made pharmacokinetic studies in 
humans to understand the metabolic capacity and 
the synergy between both drugs.
Experimental
Apparatus
Analysis was performed with a Beckman P/ACE 
5510 capillary electrophoresis system (Palo Alto, 
CA, USA), equipped with a diode array detector 
(DAD) and controlled by a Dell Dimension P133V 
computer with P/ACE station software. The 57 cm 
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Figure 1. Chemical structures of letrozole, imipramine and their metabolites.93
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(50 to the detector) × 75 μm ID fused-silica 
separation capillary was maintained in a cartridge 
with a 100 μm × 800 μm detection window. The 
use of a photodiode detector allowed us to conﬁ  rm 
the identity of the peaks, not only by its migration 
time, but also by the overlay of the UV-Vis spectra 
of the samples with a standard.
The extraction and pre-concentration processes 
were achieved with a Supelco (Bellefonte, PA, 
U.S.A) vacuum manifold coupled to a vacuum 
pump. The C18 cartridges were obtained from 
Waters (Milford, MA, U.S.A).
A Crison micro-pH 2002 instrument (Alella, 
Barcelona) was used for pH measurements.
Centrifugation of urine was carried out by a 
Selecta apparatus (Abrera, Barcelona).
Chemicals and solutions
LE, IMI and their metabolites were kindly provided 
by Novartis Pharma (Basel, Switzerland).
Standard stock solutions (100 mg/L) of LE and 
ME were prepared in 50% (v/v) ethanol-water. 
Standard stock solutions (100 mg/L) of IMI, DES, 
2-OH-IMI were prepared in water (Milli-Q 
quality). A standard solution (100 mg/L) of 
10-OH-IMI was prepared in 50% (v/v) methanol-
water. The resulting solutions were stored at 4 ºC. 
Working standard solutions were prepared daily 
by diluting suitable aliquots of standard stock solu-
tion with Milli-Q water.
A 15 mM borate buffer (pH 9.2) containing 25 mM 
SDS and 15% of 2-propanol was used as the back-
ground electrolyte and prepared daily.
All these reagents were from Panreac (Barce-
lona, Spain). All chemicals and solvents used were 
of analytical reagent grade.
Operating conditions
Before ﬁ  rst use the capillary was conditioned by 
ﬂ  ushing with 0.1 M NaOH for 20 min, then with 
water for 10 min, and ﬁ  nally with the background 
electrolyte solution for 10 min. The rinse step was 
performed by use of different vials from the separa-
tion vials, in order to keep the level of buffer in the 
anodic separation vial constant. At the start of each 
sequence the capillary was washed with 0.1 M NaOH 
for 3 min then with electrolyte separation buffer for 
5 min, to restore the capillary wall surface and re-
equilibrate the capillary between sample injections.
The sample vials were refrigerated at 8 ºC inside 
the equipment. Separations were performed 
at 28 kV for 10 min at 40 ºC. Under these conditions 
the current was 51 μA. Duplicate injections of the 
solutions were performed and average peak areas 
were used for the quantiﬁ  cation.
Treatment of the urine samples 
and SPE procedure
Fresh human urine samples were obtained from 
different volunteers who had or had not taken LE 
or IMI, and submitted directly to solid phase 
extraction after a preliminary centrifugation step 
(1398 g, 10 min, 20 ºC).
The extraction of our compounds from the urine 
samples was performed in a reverse-phase C18 
cartridge (Waters Sep-Pak Plus). The cartridge was 
preconditioned with 5 mL of methanol followed 
by 5 mL of 10 mM phosphate buffer solu-
tion (pH 7.0).
Different volumes (between 2 and 10 mL) of 
urine were slowly loaded into the conditioned 
cartridge. It was then washed with 8 mL of 10 mM 
phosphate buffer (pH 7.0) and 2 mL of a 20/80% 
(v/v) methanol-water solution. LE, IMI and their 
metabolites were eluted with 3 mL of methanol. 
Later on, this extract was evaporated to dryness 
with a gentle nitrogen stream and ﬁ  nally, they were 
reconstituted with 1 mL of Milli-Q water and 
transferred to the appropriate vials to be injected 
into the capillary electrophoresis equipment.
Results and Discussion
Optimisation of the MEKC procedure
Firstly, to achieve a suitable separation of the 
studied drugs, the effect of background electrolyte 
(BGE) pH (in the range 5 to 10) on resolution 
between peaks and analysis time was investigated 
using CZE. As BGEs were tested various salts 
(borate, phosphate, acetate,) to get buffer with dif-
ferent pH values. Baseline separation of IMI, LE 
and their metabolites was not achieved at any of 
the pH values arrayed. This was particularly pre-
dominant in the analysis of LE and their metabo-
lites at all pH values; this is because they exist in 
a non- ionic form, and so MEKC was conducted 
for the separation of these drugs. SDS was used as 
surfactant in the separation electrolyte. In these 
preliminary studies it was observed that the best 
separation of our compounds was achieved at 
pH value of 9.2, which is provided by borate buffer 94
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solution. Therefore, this pH value was selected for 
the following studies.
Effect of SDS concentration
The effect of SDS concentration on migration 
times and resolution between peaks was researched 
over the range 10–40 mM maintaining constant 
pH (9.2), 15 mM borate buffer, as separation 
electrolyte, and 30 kV and 40 ºC as separation 
voltage and cartridge temperature, respectively. 
25 mM was selected as optimal SDS concentration. 
Lower concentrations of this surfactant provided 
shorter total analysis times but there were several 
peak overlaps, and higher SDS concentrations 
resulted in increased resolution between peaks but 
resulted in excessive analysis time was obtained.
Effect of ionic strength of electrolyte
The effect of the concentration of buffer solution 
(pH 9.2) from 5–40 mM on resolution of peaks and 
migration times was studied, with constant SDS 
concentration of 25 mM. A buffer concentration of 
15 mM was selected as optimal because it renders 
good peak shapes, low current (51 μA) and better 
resolution between all peaks.
Effect of organic modiﬁ  ers
The addition of an organic modiﬁ  er to the BGE 
may improve the selectivity and resolution; there-
fore the effects of several organic solvent (metha-
nol, acetonitrile and 2-propanol) at different 
concentrations in the running buffer were exam-
ined. Elevated concentrations of solvent (20%) 
were not used because these may cause the break-
down of micelles. When we used MeOH and ACN 
large and asymmetric peaks were obtained and did 
not allow the separation of all the studied com-
pounds. Best selectivity, the most symmetric peaks, 
and the best resolution between peaks, was 
obtained at low 2-propanol concentration. Figure 2 
shown the resolution between the peaks LE-ME, 
and IMI-DES over several concentration of 2-pro-
panol, resolutions more affected by this parameters. 
15% (v/v) 2-propanol was chosen optimal for 
resolution, analysis times and peak shapes.
Effect of voltage
The effect of the voltage applied from 10 to 30 kV 
was investigated. As expected, increasing the 
applied voltage, increases EOF, leading to shorter 
analysis time and higher efﬁ  ciencies. A voltage of 
28 kV yielded the best compromise for run time, 
separation current and resolution and was used for 
all experimental stages for the development of this 
method.
Effect of capillary temperature
Changes in capillary temperature can cause varia-
tions in efﬁ  ciency, migration times and injection 
volumes. The effect of the temperature on the 
separation was investigated in the range of 20 to 
45 ºC. When, the temperature increases, the 
viscosity of buffer decreases, so the resistance of 
the buffer decreases and as the electric ﬁ  eld is 
constant, the current increase. At higher tempera-
tures, the migration time of all the studied com-
pounds decreases (Fig. 3). 40 ºC was selected 
because it provided the best resolution in the 
shortest total analysis time, and the generated cur-
rent is lower than 52.8 μA.
Effect of injection time
To decrease the detection and quantiﬁ  cation limits 
in the biological ﬂ  uid studied (human urine), the 
injection times were investigated. This parameter 
was varied between 3 and 8 s at a constant pressure 
of 0.5 psi (1 psi = 6894.8 Pa).
As expected, when the injection time increased, 
the peak areas of all compounds also increased, 
Figure 2. Effects of % 2-propanol on resolution between the peaks 
LE-ME and IMI-DES.
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but when this parameter was higher than 6s a loss 
of resolution was observed. For this reason, 6s was 
chosen for injection time.
Solid Phase Extraction of the human 
urine samples (SPE)
Firstly, the electrophoretic procedure was applied 
to the analysis of human urine which had not been 
submitted to any special treatment; but due to the 
presence of large quantities of interfering com-
pounds, and the low concentration of the studied 
compounds, it was necessary to carry out an extrac-
tion procedure for these compounds. Silica based 
apolar phases (C18) were used to extract LE, IMI 
and their respective metabolites; because this sor-
bent is of interest for the extraction of apolar 
compounds from a polar matrix such as urine. This 
cartridge has a silica-based bonded phase with 
strong hydrophobicity and was used to adsorb 
analytes of even weak hydrophobicity from aque-
ous solutions
Variables such as organic solvent; washing 
stages, using different solvents; organic solvent-
water ratio, to elute our analytes free from interfer-
ences; and final volume of the extract were 
studied.
An improved electropherogram was obtained 
when loading the urine sample on the silica based 
apolar phases column previously washed with 8 mL 
of 10 mM phosphate buffer (pH 7.0) and 2.5 mL 
of a 20% methanol-water solution to minimize 
interferences. Finally, letrozole, imipramine and 
their metabolites were eluted with 3 mL methanol. 
Later on, this extract was evaporated to dryness 
with 1 mL of Milli-Q water and transferred to the 
appropriate vials to be injected into the capillary 
electrophoresis equipment. The maximal capacity 
of the silica based apolar phase column was inves-
tigated, and was determined to be 8 mL, therefore 
it was possible to preconcentrate eight times.
Validation of the proposed 
electrophoretic procedure
Selectivity
Representative electropherograms corresponding 
to the extracts from blank urine and urine spiked 
with 3 mg/L of each of the studied compounds are 
presented in Figure 4. At the migration times of 
our analytes, no interfering peaks of endogenous 
compounds were observed in blank human urine 
of the three volunteers.
Selectivity was also determined, by measure-
ment of peak homogeneity using the techniques of 
normalization and comparison of spectra from 
different peak sections and absorbance at two 
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wavelengths [16]. Both techniques proved to have 
a high level of purity of the peaks corresponding 
to the compounds studied in urine. Therefore, no 
interferences by matrix effect were observed.
Stability of the solutions
The stability of stock and diluted solutions of LE, 
IMI and their metabolites were investigated and 
results revealed that both solutions were stable for 
at least one month and seven days, for LE and IMI 
respectively.
The stability of LE, IMI and their metabolites 
at ambient temperature in urine samples were 
performed at several levels. The results revealed 
that all the compounds were stable for at least one 
day. It was conﬁ  rmed that the repeated freeze and 
thawing of urine samples spiked with LE, IMI and 
their metabolites, did not affect the stability 
of these compounds.
Precision
To test the electrophoretic procedure suitability, 
eight injections of urine were spiked with LE, IMI 
and their metabolites, so that the concentrations at 
the end of the analytical pre-treatment were made 
2.5 mg/L. The precision of the migration times and 
peak areas were very satisfactory with RSD 
between 0.26% and 0.81%, and 1.08% and 2.32% 
respectively, for all the studied compounds.
The operation for intermediate precision was 
repeated on different days and RSD values of less 
than 0.88% were obtained for migration times and 
less than 5.78% for peak areas. Comparison of the 
two sets of data with the aim of detecting random 
errors was carried out by applying the Snedecor F-test 
on these RSD values. Signiﬁ  cant differences were 
not found in any case at a conﬁ  dence level of 95%.
The precision of the total analytical procedure 
(including SPE) was evaluated by submitting 
six different spiked urine samples (2.5 mg/L for 
every compound) to this overall extraction-
electrophoretic process (in duplicate). The 
results showed that RSD of the peak area for 
each compound was always less than 4.11%. 
Likewise, RSD obtained for the migration times 
were under 0.53%.
The results obtained for the repeatability, 
intermediate precision and precision of the total 
analytical procedure are summarized in Table 1 
and expressed in terms of RSD.
Linearity
The linear behaviour was determined from duplicate 
injections of spiked human urine samples (previ-
ously submitted to the SPE treatment) at six differ-
ent concentration ranging from 1.0 to 5.0 mg/L for 
every compound. The obtained linear regression 
equations and regression coefﬁ  cients are presented 
in Table 2.
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sample spiked with 3 mg/L of LE, IMI and metabolites. Operating 
conditions: hydrodynamic injection (6 s, 0.5 psi); separation: 15 mM 
(pH 9.2) borate buffer, 25 mM SDS and 15% 2-propanol, 28 kV as 
voltage of separation, 40 ºC as capillary temperature and detection 
at 205 nm.97
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of standard solutions of LE, IMI and their 
metabolites were added into human urine samples. 
These samples were analysed using the extraction, 
pre-concentration and electrophoretic procedures 
described in this work. The concentrations found 
in the test solutions were then calculated by 
reference to the duplicate bracketing standard solu-
tions and the recoveries obtained are summarized 
in the Table 3.
Integral robustness-ruggedness evaluation
The United States Pharmacopeia (UPS) deﬁ  nes 
ruggedness as “the degree of reproducibility of 
the test results obtained by the analysis of the same 
samples under a variety of normal test conditions 
such as different days, several reagent lots, different 
lots, different instruments, various laboratories, 
different elapsed assay times…” where all of these 
factors are external to the written analytical 
method.
The robustness of a method is deﬁ  ned by both 
the USP and ICH Tripartite guidelines as “a measure 
In order to conﬁ  rm linearity according to the 
Analytical Methods Committee (AMC), [17] the test 
for “the lack of ﬁ  t” was satisfactorily overcome.
Limits of detection and quantitation
The limits of detection (LODs) and quantiﬁ  cation 
(LOQs) were calculated by measuring the noise in 
different blanks, and taking into account a factor 
of 3 and 10 for LODs and LOQs, respectively, and 
by using standards obtained in order to convert to 
concentration units. The LODs and LOQs have 
been calculated taking into account the overall 
process (extraction, preconcentration and MEKC 
step), and by passing through the SPE column 8 mL 
of urine samples (Table 2).
Accuracy
The accuracy expresses the closeness of agreement 
between the value found and the value that it is 
accepted as a reference value. In order to test the 
accuracy of the proposed method, several aliquots 
Table 1. Precision.
Compounds Repeatability
a
RSD(%), n = 8
Intermediate precision
a
RSD(%), n = 16
Precision
b 
SD(%), n = 6
tm
* PA
** tm
* PA
** tm
* PA
**
LE 0.26 1.74 0.44 5.07 0.36 1.60
ME 0.81 1.55 0.62 2.53 0.24 2.02
10-OH-IMI 0.40 1.79 0.86 5.35 0.42 3.43
2-OH-IMI 0.38 2.31 0.88 4.67 0.53 3.16
IMI 0.42 1.08 0.74 4.20 0.51 1.94
DES 0.38 2.32 0.71 5.78 0.50 4.11
(*) tm, migration time; (**) PA, peak area.
a) Relative to the single electrophoretic procedure.
b) Precision of the total analytical procedure (including the SPE).
Table 2. Linearity, LODs and LOQs values.
Peaks Equation Regresion 
coefﬁ  cient
LODs* 
(ng/mL)
LOQs** 
(ng/mL)
LE Y = (2908.0  ±  195.0) × −(718.7 ± 601.9) 0.982 12.5 37.5
ME Y = (2811.9 ± 252.8) × −(247.3 ± 117.9) 0.989 12.5 37.5
IMI Y = (2056.3 ± 110.8) × −(148.3 ± 141.1) 0.991 37.5 112.5
DES Y = (1851.6 ± 32.9) × −(110.7 ± 101.3) 0.998 37.5 112.5
2-OH-IMI Y = (1553.0 ± 50.5) × −(183.9 ± 112.5) 0.985 37.5 112.5
10-OH-IMI Y = (2008.8 ± 40.12) × −(156.7 ± 101.0) 0.997 37.5 112.5
*LODs: limits of detection.
**LOQs: limits of quantiﬁ  cation.98
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of its capacity to remain unaffected by small but 
deliberate variations in method parameters and 
provides an indication of its reliability during nor-
mal use [18]”. Ruggedness can therefore be 
regarded as a measure of the absence of external 
inﬂ  uences on the test results, whereas robustness 
measures the lack of internal inﬂ  uences on these 
results.
In this work we have tested the inﬂ  uence of 
variations in both internal and external parameters 
of the method (e.g. pH and ionic strength of buffer, 
SDS concentration, voltage, capillary temperature, 
different days for analysis, etc), whose inﬂ  uence 
has been studied at different levels.
The Plackett-Burman fractional factorial model, 
which is based on balanced incomplete blocks, was 
employed to evaluate this aspect of the method.
For statistical reasons (concerning effects on 
interpretation), designs with fewer than eight exper-
iments are not used, while those with more than 24 
experiments were considered unpractical [19, 20]. 
To date, this model has been usually satisfactorily 
applied just in the evaluation of robustness.
A novel Plackett-Burman design that involves 
the evaluation of both robustness and ruggedness 
effects (eleven factors and twelve experiments, 
N   =   12) is presented in Table 4 (http://www.
locumusa.com/pdf/general/article01.pdf). The 
Table 4. Experimental design for the whole robustness-ruggedness evaluation using the Plackett-Burman 
model.
Experiment 
number
External/internal changes or variations (11)
Selected factors
ABCDEFGHI JK
1 ++−+++−−−+−
2 −++−+++−−−+
3 +−++−+++−−−
4 −+−++−+++−−
5 −−+−++−+++−
6 −−−+−++−+++
7 +−−−+−++−++
8 ++−−−+−++−+
9 +++−−−+−++−
10 −+++−−−+−++
11 +−+++−−−+−+
12 −−−−−−−−−−−
−, +: Levels for the factors.
Table 3. Accuracy of human urine samples.
Compounds Sample 1 Sample 2 Sample 3 Sample 4
Added 
(mg/L)
Recoveries 
(%)
*
Added 
(mg/L)
Recoveries 
(%)
*
Added 
(mg/L)
Recoveries 
(%)*
Added 
(mg/L)
Recoveries 
(%)*
LE 1.5 96.31 ± 0.05 2.5 102.90 ± 0.08 3.5 100.43 ± 0.03 4.5 98.50 ± 0.02
ME 1.5 102.20 ± 0.02 2.5 95.52 ± 0.01 3.5 99.41 ± 0.09 4.5 100.82 ± 0.07
IMI 1.5 99.50 ± 0.01 2.5 102.53 ± 0.03 3.5 102.12 ± 0.11 4.5 101.50 ± 0.02
DES 1.5 104.84 ± 0.06 2.5 97.80 ± 0.05 3.5 98.10 ± 0.03 4.5 99.73 ± 0.05
2-OH-IMI 1.5 94.91 ± 0.03 2.5 94.21 ± 0.06 3.5 95.37 ± 0.01 4.5 98.21 ± 0.03
10-0H-IMI 1.5 96.23 ± 0.04 2.5 97.60 ± 0.10 3.5 100.82 ± 0.05 4.5 102.30 ± 0.08
*n = 3.99
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choice of variables (factors) and the levels at which 
they are tested is very important for a reliable 
robustness/ruggedness test. In our case, the vari-
ables selected as factors are instrumental and 
chemical parameters that are signiﬁ  cant in the 
performance of the proposed method. The selection 
about the levels of these factors should reﬂ  ect slight 
variations, which could be usually observed. The 
external (ruggedness) and internal (robustness) 
factors (A-K) selected for our model are presented 
in Table 5, which also shows the (+) and (−) levels 
for every factor that are, respectively, upper and 
lower values with regard to optimal in the 
procedure.
The effects of varying the levels on the most 
critical electrophoretic responses of the method 
were investigated.
The “ranked effects” (main effects calculated 
according to Plackett and Burman) for every 
selected factor on a specific electrophoretic 
response were calculated by simple addition of 
its (−) and (+) assay test results, upon the design 
shown in Table 4. The total result obtained for 
every factor was divided by half the number of 
samples. The M values are statistic constants for 
any given design table with a number of elements; 
there are eleven factors in our case [21]. Finally, 
the obtained ranked effects for the 11 selected 
factors were plotted (on the x-axis, in increasing 
order) against the M values (on the y-axis) for each 
critical electrophoretic response. The results from 
this plot must be near to a straight line. If a value 
lies outside this straight line, it can be concluded 
that the method is not rugged/or robust at this point 
(as classiﬁ  ed by its corresponding factor). How-
ever, if the results from the plot form a (nearly) 
straight line, it can be concluded that the analytical 
method is rugged and robust over the conditions 
tested in the run design.
The robustness/ruggedness evaluation was 
performed in our case, by carrying out duplicate 
injections of urine samples spiked with 3 mg/L of 
all compounds. The described robustness/rugged-
ness test showed our SPE-electrophoretic method 
to be both robust and rugged for the critical elec-
trophoretic responses assessed for all the variations 
tested in this study.
As an example, the plot corresponding to the 
ranked effects of the 11 selected factors vs. M 
values for the resolution between IMI and DES, is 
shown in Figure 5. It can be seen from this plot 
that all the points lie on a straight line and, 
therefore, our analytical method can be considered 
robust and rugged about this electrophoretic 
response.
In general terms, the described robustness/
ruggedness test showed our electrophoretic method 
is both robust and rugged enough for the critical 
electrophoretic responses; being assessed for all 
the variations tested in this study.
Analysis of Human Urine Samples
To demonstrate the applicability of the extraction, 
preconcentration and MEKC procedure developed 
in this report, urine samples of two volunteers 
(patients undergoing medical treatment) were 
analysed.
Table 5. Variables selected as factors and values chosen as levels.
Factors External/internal Optimal Level (−) Level (+)
(A) Different days External – 2 1
(B) Different buffers External – 2 1
(C) Different patiens External – 2 1
(D) MeOH(%) washing Internal 20 18 22
(E) Elution volume (SPE) Internal 3 2.8 3.2
(F) Injection time (s) Internal 6 5 7
(G) Voltage (kV) Internal 28 26 30
(H) [Buffer] (mM) Internal 15 13 17
(I) [SDS] (mM) Internal 25 23 27
(J) Percent 2-propanol Internal 15 13 17
(K) λ detection (nm) Internal 205 203 207100
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Then, urine of two different volunteers 
undergoing medical treatment with LE or IMI were 
analysed. The ﬁ  rst is a woman A, that receives 
2.5 mg per day of LE orally (year 3 of treatment), 
and the second is a woman B, takes 25 mg per day 
of IMI orally (recent commencement of treatment). 
The urine samples were collected up to 7 hours 
after oral single dose administration of LE 
(woman A) or 5 hours after oral single dose admin-
istration of IMI (woman B). The concentrations of 
each compound found in the analyzed urine sam-
ples are shown in Table 6. All determinations were 
carried out in duplicate. To evaluate the possible 
matrix effect, the method of standard addition was 
used for the determination of these compounds in 
some urine samples, the results obtained are also 
shown in Table 6. As shown, these results coincide 
with those obtained by direct measurement by the 
proposed method.
Two electropherograms of these experiments 
under conditions optimised in this paper are shown 
in Figure 6.
Conclusions
A simple, speciﬁ  c and sensitive MEKC method 
has been developed for the analysis of LE, IMI, 
and their metabolites in human urine. Although, 
LE and IMI have previously been determined 
independently, this is the ﬁ  rst report that enables 
the determination of LE and its main metabolite, 
along with IMI and their metabolites, together, in 
human urine. MEKC proved to be an effective 
technique for the simultaneous analysis of these 
drugs.
Before MEKC analysis, a reproducible SPE 
method for LE, IMI and their metabolites was 
developed, which permits the quantiﬁ  cation of 
these compounds at clinical concentration. The 
method provided excellent linearity, accuracy, 
speciﬁ  city, sensitivity, precision and ruggedness.
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Fit 1: Linear
Equation Y = 1.608056541 * X - 0.3007211918
Number of data points used = 11
Average X = 0.187009
Average Y = -2.01859E-017
Residual sum of squares = 0.156755
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Coef of determination, R-squared = 0.982366
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Figure 5. Plot corresponding to M values for the resolution Rs 
between IMI and DES vs. ranked effects of the 11 selected factors. 
Table 6. Analysis of human urine samples.
Woman A Woman B
Standard 
addition (mg/L)
Direct
measurement (mg/L)
Standard 
addition (mg/L)
Direct
measurement (mg/L)
LE 0.40 0.40 – –
ME 0.16 0.15 – –
IMI – – 0.55 0.56
DES – – 0.61 0.61
10-OH-IMI – – * *
2-OH-IMI – – * *
*Amount detected but not quantiﬁ  ed.101
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Figure 6. Electropherogram corresponding: a) urine sample from a 
woman on imipramine treatment (recently treatment) after 5 h of the 
administration of 50 mg dosage, b) urine sample from a woman on 
letrozole treatment (3 year of treatment) after 7 h of the administration 
of 2.5 mg dosage.
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